

Fengmin Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2311171/publications.pdf>

Version: 2024-02-01

42
papers

2,602
citations

218677

26
h-index

276875

41
g-index

42
all docs

42
docs citations

42
times ranked

5457
citing authors

#	ARTICLE	IF	CITATIONS
1	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 480-492.	3.4	284
2	Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors. <i>Cancer</i> , 2014, 120, 425-432.	4.1	259
3	The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. <i>Cancer</i> , 2013, 119, 4333-4340.	4.1	235
4	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. <i>Cancer</i> , 2012, 118, 5937-5946.	4.1	174
5	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2353-2360.	1.6	167
6	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. <i>Journal of Clinical Oncology</i> , 2018, 36, 1556-1563.	1.6	134
7	Phase III Comparison of Tamoxifen Versus Tamoxifen Plus Ovarian Function Suppression in Premenopausal Women With Node-Negative, Hormone Receptor-Positive Breast Cancer (E-3193). <i>Journal of Clinical Oncology</i> , 2016, 34, 3948-3958.	1.6	118
8	Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. <i>Clinical Cancer Research</i> , 2015, 21, 5082-5091.	7.0	106
9	Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). <i>Journal of Clinical Oncology</i> , 2016, 34, 4076-4085.	1.6	101
10	A Randomized Phase II Trial of Multipitope Vaccination with Melanoma Peptides for Cytotoxic T Cells and Helper T Cells for Patients with Metastatic Melanoma (E1602). <i>Clinical Cancer Research</i> , 2013, 19, 4228-4238.	7.0	98
11	Race and Hormone Receptor-Positive Breast Cancer Outcomes in a Randomized Chemotherapy Trial. <i>Journal of the National Cancer Institute</i> , 2012, 104, 406-414.	6.3	89
12	E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 1.	5.2	84
13	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). <i>Journal of Clinical Oncology</i> , 2017, 35, 718-726.	1.6	70
14	Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). <i>Breast Cancer Research and Treatment</i> , 2018, 169, 537-548.	2.5	58
15	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3171-3181.	1.6	54
16	Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131). <i>Clinical Cancer Research</i> , 2020, 26, 1812-1819.	7.0	47
17	Surrogate End Points and Their Validation in Oncology Clinical Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 1436-1437.	1.6	46
18	Symptom burden among young adults with breast or colorectal cancer. <i>Cancer</i> , 2014, 120, 2255-2263.	4.1	37

#	ARTICLE	IF	CITATIONS
19	Anxiety and Health-Related Quality of Life Among Patients With Low-â€Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT). <i>Journal of Clinical Oncology</i> , 2015, 33, 740-748.	1.6	36
20	Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). <i>Clinical Cancer Research</i> , 2017, 23, 5034-5043.	7.0	34
21	The Validity and Utility of the M. D. Anderson Symptom Inventory in Patients With Breast Cancer: Evidence From the Symptom Outcomes and Practice Patterns Data From the Eastern Cooperative Oncology Group. <i>Clinical Breast Cancer</i> , 2013, 13, 325-334.	2.4	33
22	Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. <i>Clinical Cancer Research</i> , 2014, 20, 3328-3337.	7.0	33
23	Child Mortality Estimation: Methods Used to Adjust for Bias due to AIDS in Estimating Trends in Under-Five Mortality. <i>PLoS Medicine</i> , 2012, 9, e1001298.	8.4	31
24	The Validity and Utility of the MD Anderson Symptom Inventory in Patients With Prostate Cancer: Evidence From the Symptom Outcomes and Practice Patterns (SOAPP) Data From the Eastern Cooperative Oncology Group. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 41-49.	1.9	31
25	Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 988-998.	1.2	31
26	Determinants of Pain Severity Changes in Ambulatory Patients With Cancer: An Analysis From Eastern Cooperative Oncology Group Trial E2Z02. <i>Journal of Clinical Oncology</i> , 2014, 32, 312-319.	1.6	29
27	Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. <i>Journal of Cancer Survivorship</i> , 2015, 9, 1-10.	2.9	28
28	Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. <i>Journal of Pain and Symptom Management</i> , 2015, 49, 1016-1024.	1.2	20
29	Association between patients' perception of the comorbidity burden and symptoms in outpatients with common solid tumors. <i>Cancer</i> , 2017, 123, 3835-3842.	4.1	20
30	Predictors of significant worsening of patient-reported fatigue over a 1-month timeframe in ambulatory patients with common solid tumors. <i>Cancer</i> , 2014, 120, 442-450.	4.1	17
31	A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). <i>Breast Cancer Research and Treatment</i> , 2017, 165, 375-382.	2.5	17
32	Association of fatigue and depression with circulating levels of proinflammatory cytokines and epidermal growth factor receptor ligands: a correlative study of a placebo-controlled fatigue trial. <i>Cancer Management and Research</i> , 2017, Volume 9, 1-10.	1.9	15
33	Dyspareunia, Urinary Sensory Symptoms, and Incontinence Among Young Chinese Women. <i>Archives of Sexual Behavior</i> , 2006, 35, 561-567.	1.9	14
34	Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). <i>Oncologist</i> , 2020, 25, e798-e807.	3.7	12
35	Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer. <i>Cancer Medicine</i> , 2021, 10, 45-52.	2.8	11
36	Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. <i>Cancer Medicine</i> , 2020, 9, 7511-7523.	2.8	8

#	ARTICLE	IF	CITATIONS
37	Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. <i>Supportive Care in Cancer</i> , 2018, 26, 1889-1895.	2.2	6
38	Intra- and Interlaboratory Reproducibility of the Sensitivity to Endocrine Therapy Assay for Stage II/III Breast Cancer. <i>Clinical Chemistry</i> , 2021, 67, 1240-1248.	3.2	3
39	Reply to T. Shimoi et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	1.6	3
40	Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. <i>PLoS ONE</i> , 2013, 8, e69748.	2.5	3
41	Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2â€“negative breast cancer: A trajectory analysis of adverse events. <i>Cancer</i> , 2021, 127, 4546-4556.	4.1	3
42	Reply to B. UlaÅŸ Kahya et al and A. Soran et al. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	3